Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 24

1.

Primary neuroprotection: the Holy Grail of multiple sclerosis therapy.

Fox RJ.

Neurology. 2010 Mar 30;74(13):1018-9. doi: 10.1212/WNL.0b013e3181d6b165. Epub 2010 Mar 3. No abstract available.

PMID:
20200341
2.

Black holes in multiple sclerosis: definition, evolution, and clinical correlations.

Sahraian MA, Radue EW, Haller S, Kappos L.

Acta Neurol Scand. 2010 Jul;122(1):1-8. doi: 10.1111/j.1600-0404.2009.01221.x. Epub 2009 Dec 5. Review.

PMID:
20003089
3.

250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study.

O'Connor P, Filippi M, Arnason B, Comi G, Cook S, Goodin D, Hartung HP, Jeffery D, Kappos L, Boateng F, Filippov V, Groth M, Knappertz V, Kraus C, Sandbrink R, Pohl C, Bogumil T; BEYOND Study Group, O'Connor P, Filippi M, Arnason B, Cook S, Goodin D, Hartung HP, Kappos L, Jeffery D, Comi G.

Lancet Neurol. 2009 Oct;8(10):889-97. doi: 10.1016/S1474-4422(09)70226-1. Epub 2009 Sep 2. Erratum in: Lancet Neurol. 2011 Feb;10(2):115. Lancet Neurol. 2009 Nov;8(11):981. Lancet Neurol. 2012 Jan;11(1):27. Cree, B [added]; Harung, H-P [corrected to Hartung, H-P].

PMID:
19729344
4.

New acute and chronic black holes in patients with multiple sclerosis randomised to interferon beta-1b or glatiramer acetate.

Cadavid D, Cheriyan J, Skurnick J, Lincoln JA, Wolansky LJ, Cook SD.

J Neurol Neurosurg Psychiatry. 2009 Dec;80(12):1337-43. doi: 10.1136/jnnp.2008.171090. Epub 2009 Aug 16.

PMID:
19687024
5.

Gadolinium-enhancing or active T2 magnetic resonance imaging lesions in multiple sclerosis clinical trials?

Bonzano L, Roccatagliata L, Mancardi GL, Sormani MP.

Mult Scler. 2009 Sep;15(9):1043-7. doi: 10.1177/1352458509106610. Epub 2009 Jul 1.

PMID:
19570818
6.

Imaging outcomes for neuroprotection and repair in multiple sclerosis trials.

Barkhof F, Calabresi PA, Miller DH, Reingold SC.

Nat Rev Neurol. 2009 May;5(5):256-66. doi: 10.1038/nrneurol.2009.41. Review.

PMID:
19488083
7.

Interferon-beta therapy up-regulates BDNF secretion from PBMCs of MS patients through a CD40-dependent mechanism.

Azoulay D, Mausner-Fainberg K, Urshansky N, Fahoum F, Karni A.

J Neuroimmunol. 2009 Jun 25;211(1-2):114-9. doi: 10.1016/j.jneuroim.2009.04.004. Epub 2009 May 5.

PMID:
19419774
8.

Regulation of matrix metalloproteinases and their inhibitors by interferon-beta: a longitudinal study in multiple sclerosis patients.

Bernal F, Elias B, Hartung HP, Kieseier BC.

Mult Scler. 2009 Jun;15(6):721-7. doi: 10.1177/1352458509102920. Epub 2009 Apr 21.

PMID:
19383643
9.

Efficacy of treatment of MS with IFNbeta-1b or glatiramer acetate by monthly brain MRI in the BECOME study.

Cadavid D, Wolansky LJ, Skurnick J, Lincoln J, Cheriyan J, Szczepanowski K, Kamin SS, Pachner AR, Halper J, Cook SD.

Neurology. 2009 Jun 9;72(23):1976-83. doi: 10.1212/01.wnl.0000345970.73354.17. Epub 2009 Mar 11.

PMID:
19279320
10.

Persistent T1 hypointensity as an MRI marker for treatment efficacy in multiple sclerosis.

van den Elskamp IJ, Lembcke J, Dattola V, Beckmann K, Pohl C, Hong W, Sandbrink R, Wagner K, Knol DL, Uitdehaag B, Barkhof F.

Mult Scler. 2008 Jul;14(6):764-9. doi: 10.1177/1352458507087842.

PMID:
18611989
11.

Interferon-beta induces brain-derived neurotrophic factor in peripheral blood mononuclear cells of multiple sclerosis patients.

Lalive PH, Kantengwa S, Benkhoucha M, Juillard C, Chofflon M.

J Neuroimmunol. 2008 Jul 15;197(2):147-51. doi: 10.1016/j.jneuroim.2008.04.033. Epub 2008 Jun 13.

PMID:
18555540
12.

Molecular characterization and bioinformatics analysis of Ncoa7B, a novel ovulation-associated and reproduction system-specific Ncoa7 isoform.

Shkolnik K, Ben-Dor S, Galiani D, Hourvitz A, Dekel N.

Reproduction. 2008 Mar;135(3):321-33. doi: 10.1530/REP-07-0402.

13.

Effects of interferon beta-1b on black holes in multiple sclerosis over a 6-year period with monthly evaluations.

Bagnato F, Gupta S, Richert ND, Stone RD, Ohayon JM, Frank JA, McFarland HF.

Arch Neurol. 2005 Nov;62(11):1684-8. Epub 2005 Sep 12.

PMID:
16157739
14.

Interferon beta promotes nerve growth factor secretion early in the course of multiple sclerosis.

Biernacki K, Antel JP, Blain M, Narayanan S, Arnold DL, Prat A.

Arch Neurol. 2005 Apr;62(4):563-8.

PMID:
15824253
15.

Effect of natalizumab on conversion of gadolinium enhancing lesions to T1 hypointense lesions in relapsing multiple sclerosis.

Dalton CM, Miszkiel KA, Barker GJ, MacManus DG, Pepple TI, Panzara M, Yang M, Hulme A, O'Connor P, Miller DH.

J Neurol. 2004 Apr;251(4):407-13.

PMID:
15083284
16.

Glatiramer acetate-specific T cells in the brain express T helper 2/3 cytokines and brain-derived neurotrophic factor in situ.

Aharoni R, Kayhan B, Eilam R, Sela M, Arnon R.

Proc Natl Acad Sci U S A. 2003 Nov 25;100(24):14157-62. Epub 2003 Nov 12. Erratum in: Proc Natl Acad Sci U S A. 2005 Aug 23;102(34):12288.

17.

Glatiramer acetate reduces the proportion of new MS lesions evolving into "black holes".

Filippi M, Rovaris M, Rocca MA, Sormani MP, Wolinsky JS, Comi G; Eurpoean/Canadian Glatiramer Acetate Study Group.

Neurology. 2001 Aug 28;57(4):731-3.

PMID:
11524494
18.

T1 hypointensities and axonal loss.

Barkhof F, Karas GB, van Walderveen MA.

Neuroimaging Clin N Am. 2000 Nov;10(4):739-52 ,ix. Review.

PMID:
11359722
20.

Histopathologic correlate of hypointense lesions on T1-weighted spin-echo MRI in multiple sclerosis.

van Walderveen MA, Kamphorst W, Scheltens P, van Waesberghe JH, Ravid R, Valk J, Polman CH, Barkhof F.

Neurology. 1998 May;50(5):1282-8.

PMID:
9595975

Supplemental Content

Support Center